|
Rehabilitation
Citations 11-20 of 54 total displayed.
|
Past content
(since Jan 2001):
|
- EDITORIALS
TPMT testing in rheumatology: any better than routine monitoring?
- K. Payne, W. Newman, E. Fargher, K. Tricker, I. N. Bruce, and W. E. R. Ollier
Rheumatology 2007; 46: 727-729.
[Extract]
[Full Text]
- EDITORIALS
Do case control studies on coxibs tell us anything new?
- K. Brune
Rheumatology 2007; 46: 730.
[Extract]
[Full Text]
- CLINICAL
Acupuncture for fibromyalgia—a systematic review of randomized clinical trials
- E. Mayhew and E. Ernst
Rheumatology 2007; 46: 801-804.
[Abstract]
[Full Text]
- CLINICAL
A prospective double blind placebo-controlled randomized trial of ultrasound in the physiotherapy treatment of shoulder pain
- R. Ainsworth, K. Dziedzic, L. Hiller, J. Daniels, A. Bruton, and J. Broadfield
Rheumatology 2007; 46: 815-820.
[Abstract]
[Full Text]
- MATTERS ARISING
The rehabilitation model rules in RA until biomedicine transforms tomorrow's rheumatologist into a real thaumaturgus
- J. G. Jones
Rheumatology 2007; 46: 890-891.
[Extract]
[Full Text]
- MATTERS ARISING
Rehabilitation, an old useful tool in the midst of a new therapeutic era for rheumatoid arthritis
- L. Bertinotti, F. Nacci, and M. Matucci Cerinic
Rheumatology 2007; 46: 891-892.
[Extract]
[Full Text]
- CLINICAL
Treatment of knee pain in older adults in primary care: development of an evidence-based model of care
- M. Porcheret, K. Jordan, and P. Croft in collaboration with the Primary Care Rheumatology Society
Rheumatology 2007; 46: 638-648.
[Abstract]
[Full Text]
- REVIEWS
Acupuncture treatment for chronic knee pain: a systematic review
- A. White, N. E. Foster, M. Cummings, and P. Barlas
Rheumatology 2007; 46: 384-390.
[Abstract]
[Full Text]
- CLINICAL
Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study
- E. Rahme and H. Nedjar
Rheumatology 2007; 46: 435-438.
[Abstract]
[Full Text]
- CLINICAL
Autoantibodies, metalloproteinases and bone markers in rheumatoid arthritis patients are unable to predict their responses to infliximab
- T. Lequerré, F. Jouen, M. Brazier, S. Clayssens, N. Klemmer, J.-F. Ménard, O. Mejjad, A. Daragon, F. Tron, X. Le Loët, and O. Vittecoq
Rheumatology 2007; 46: 446-453.
[Abstract]
[Full Text]
|
|
